{"entity":{"id":"nct05319730","kind":"trial","name":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab, Lenvatinib, Sacituzumab tirumotecan and Dexamethasone in oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) is a phase 1/2 interventional study registered as NCT05319730 by Merck Sharp & Dohme LLC, with 230 participants planned, started 2023-05-16 and due to reach its primary completion in 2027-06-11. Interventions recorded: Paclitaxel, Irinotecan, Pembrolizumab, MK-4830, Lenvatinib and Sacituzumab tirumotecan.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05319730","url":"https://clinicaltrials.gov/study/NCT05319730"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","lenvatinib","sacituzumab-tirumotecan","dexamethasone"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05319730","phase":"1/2","setting":"A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B","sponsor":"Merck Sharp & Dohme LLC","enrolled":230,"outcomes":[]},"route":"/trials/nct05319730/","neighbours":{"cancer":[{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"drug":[{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}